Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia

Children's oncology group study AALL0031

K. R. Schultz, A. Carroll, N. A. Heerema, W. P. Bowman, A. Aledo, W. B. Slayton, H. Sather, M. Devidas, H. W. Zheng, S. M. Davies, P. S. Gaynon, M. Trigg, R. Rutledge, D. Jorstad, N. Winick, M. J. Borowitz, S. P. Hunger, W. L. Carroll, B. Camitta

Research output: Contribution to journalArticle

178 Citations (Scopus)

Abstract

We previously reported preliminary findings that post induction imatinib mesylate (340 mg/m 2/day), in combination with intensive chemotherapy, resulted in outcomes similar to blood and marrow transplant (BMT) for pediatric patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). We now report 5-year outcomes of imatinib plus intensive chemotherapy in 91 children (1-21 years) with and without allogeneic BMT (N=91). We explore the impacts of additional chromosomal abnormalities and minimal residual disease (MRD) by flow cytometry on outcomes. The 5-year disease-free survival was similar for Cohort 5 patients, treated with chemotherapy plus imatinib (70%±12%, n=28), sibling donor BMT patients (65%±11%, n=21) and unrelated donor BMT patients (59±15%; P=0.60, n=13). Patients with additional cytogenetic abnormalities had worse outcomes (P=0.05). End induction (pre-imatinib) MRD was not prognostic for Cohort 5 or allogeneic BMT patients, although limited by small numbers. The re-induction rate following relapse was similar to other higher-risk ALL groups. Longer-term follow-up confirms our initial observation of substantially good outcomes for children and adolescents with Ph+ ALL treated with imatinib plus intensive chemotherapy with no advantage for allogeneic BMT.

Original languageEnglish (US)
Pages (from-to)1467-1471
Number of pages5
JournalLeukemia
Volume28
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bone Marrow
Pediatrics
Transplants
Drug Therapy
Residual Neoplasm
Chromosome Aberrations
Unrelated Donors
Blood Donors
Disease-Free Survival
Imatinib Mesylate
Siblings
Flow Cytometry
Observation
Recurrence

Keywords

  • acute lymphoblastic leukemia
  • blood and marrow transplantation
  • event-free survival
  • imatinib mesylate
  • Philadelphia chromosome
  • toxicity

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Schultz, K. R., Carroll, A., Heerema, N. A., Bowman, W. P., Aledo, A., Slayton, W. B., ... Camitta, B. (2014). Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's oncology group study AALL0031. Leukemia, 28(7), 1467-1471. https://doi.org/10.1038/leu.2014.30

Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia : Children's oncology group study AALL0031. / Schultz, K. R.; Carroll, A.; Heerema, N. A.; Bowman, W. P.; Aledo, A.; Slayton, W. B.; Sather, H.; Devidas, M.; Zheng, H. W.; Davies, S. M.; Gaynon, P. S.; Trigg, M.; Rutledge, R.; Jorstad, D.; Winick, N.; Borowitz, M. J.; Hunger, S. P.; Carroll, W. L.; Camitta, B.

In: Leukemia, Vol. 28, No. 7, 2014, p. 1467-1471.

Research output: Contribution to journalArticle

Schultz, KR, Carroll, A, Heerema, NA, Bowman, WP, Aledo, A, Slayton, WB, Sather, H, Devidas, M, Zheng, HW, Davies, SM, Gaynon, PS, Trigg, M, Rutledge, R, Jorstad, D, Winick, N, Borowitz, MJ, Hunger, SP, Carroll, WL & Camitta, B 2014, 'Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's oncology group study AALL0031', Leukemia, vol. 28, no. 7, pp. 1467-1471. https://doi.org/10.1038/leu.2014.30
Schultz, K. R. ; Carroll, A. ; Heerema, N. A. ; Bowman, W. P. ; Aledo, A. ; Slayton, W. B. ; Sather, H. ; Devidas, M. ; Zheng, H. W. ; Davies, S. M. ; Gaynon, P. S. ; Trigg, M. ; Rutledge, R. ; Jorstad, D. ; Winick, N. ; Borowitz, M. J. ; Hunger, S. P. ; Carroll, W. L. ; Camitta, B. / Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia : Children's oncology group study AALL0031. In: Leukemia. 2014 ; Vol. 28, No. 7. pp. 1467-1471.
@article{2de5400035ba431c9f49884a06bb769b,
title = "Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's oncology group study AALL0031",
abstract = "We previously reported preliminary findings that post induction imatinib mesylate (340 mg/m 2/day), in combination with intensive chemotherapy, resulted in outcomes similar to blood and marrow transplant (BMT) for pediatric patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). We now report 5-year outcomes of imatinib plus intensive chemotherapy in 91 children (1-21 years) with and without allogeneic BMT (N=91). We explore the impacts of additional chromosomal abnormalities and minimal residual disease (MRD) by flow cytometry on outcomes. The 5-year disease-free survival was similar for Cohort 5 patients, treated with chemotherapy plus imatinib (70{\%}±12{\%}, n=28), sibling donor BMT patients (65{\%}±11{\%}, n=21) and unrelated donor BMT patients (59±15{\%}; P=0.60, n=13). Patients with additional cytogenetic abnormalities had worse outcomes (P=0.05). End induction (pre-imatinib) MRD was not prognostic for Cohort 5 or allogeneic BMT patients, although limited by small numbers. The re-induction rate following relapse was similar to other higher-risk ALL groups. Longer-term follow-up confirms our initial observation of substantially good outcomes for children and adolescents with Ph+ ALL treated with imatinib plus intensive chemotherapy with no advantage for allogeneic BMT.",
keywords = "acute lymphoblastic leukemia, blood and marrow transplantation, event-free survival, imatinib mesylate, Philadelphia chromosome, toxicity",
author = "Schultz, {K. R.} and A. Carroll and Heerema, {N. A.} and Bowman, {W. P.} and A. Aledo and Slayton, {W. B.} and H. Sather and M. Devidas and Zheng, {H. W.} and Davies, {S. M.} and Gaynon, {P. S.} and M. Trigg and R. Rutledge and D. Jorstad and N. Winick and Borowitz, {M. J.} and Hunger, {S. P.} and Carroll, {W. L.} and B. Camitta",
year = "2014",
doi = "10.1038/leu.2014.30",
language = "English (US)",
volume = "28",
pages = "1467--1471",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia

T2 - Children's oncology group study AALL0031

AU - Schultz, K. R.

AU - Carroll, A.

AU - Heerema, N. A.

AU - Bowman, W. P.

AU - Aledo, A.

AU - Slayton, W. B.

AU - Sather, H.

AU - Devidas, M.

AU - Zheng, H. W.

AU - Davies, S. M.

AU - Gaynon, P. S.

AU - Trigg, M.

AU - Rutledge, R.

AU - Jorstad, D.

AU - Winick, N.

AU - Borowitz, M. J.

AU - Hunger, S. P.

AU - Carroll, W. L.

AU - Camitta, B.

PY - 2014

Y1 - 2014

N2 - We previously reported preliminary findings that post induction imatinib mesylate (340 mg/m 2/day), in combination with intensive chemotherapy, resulted in outcomes similar to blood and marrow transplant (BMT) for pediatric patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). We now report 5-year outcomes of imatinib plus intensive chemotherapy in 91 children (1-21 years) with and without allogeneic BMT (N=91). We explore the impacts of additional chromosomal abnormalities and minimal residual disease (MRD) by flow cytometry on outcomes. The 5-year disease-free survival was similar for Cohort 5 patients, treated with chemotherapy plus imatinib (70%±12%, n=28), sibling donor BMT patients (65%±11%, n=21) and unrelated donor BMT patients (59±15%; P=0.60, n=13). Patients with additional cytogenetic abnormalities had worse outcomes (P=0.05). End induction (pre-imatinib) MRD was not prognostic for Cohort 5 or allogeneic BMT patients, although limited by small numbers. The re-induction rate following relapse was similar to other higher-risk ALL groups. Longer-term follow-up confirms our initial observation of substantially good outcomes for children and adolescents with Ph+ ALL treated with imatinib plus intensive chemotherapy with no advantage for allogeneic BMT.

AB - We previously reported preliminary findings that post induction imatinib mesylate (340 mg/m 2/day), in combination with intensive chemotherapy, resulted in outcomes similar to blood and marrow transplant (BMT) for pediatric patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). We now report 5-year outcomes of imatinib plus intensive chemotherapy in 91 children (1-21 years) with and without allogeneic BMT (N=91). We explore the impacts of additional chromosomal abnormalities and minimal residual disease (MRD) by flow cytometry on outcomes. The 5-year disease-free survival was similar for Cohort 5 patients, treated with chemotherapy plus imatinib (70%±12%, n=28), sibling donor BMT patients (65%±11%, n=21) and unrelated donor BMT patients (59±15%; P=0.60, n=13). Patients with additional cytogenetic abnormalities had worse outcomes (P=0.05). End induction (pre-imatinib) MRD was not prognostic for Cohort 5 or allogeneic BMT patients, although limited by small numbers. The re-induction rate following relapse was similar to other higher-risk ALL groups. Longer-term follow-up confirms our initial observation of substantially good outcomes for children and adolescents with Ph+ ALL treated with imatinib plus intensive chemotherapy with no advantage for allogeneic BMT.

KW - acute lymphoblastic leukemia

KW - blood and marrow transplantation

KW - event-free survival

KW - imatinib mesylate

KW - Philadelphia chromosome

KW - toxicity

UR - http://www.scopus.com/inward/record.url?scp=84904036473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904036473&partnerID=8YFLogxK

U2 - 10.1038/leu.2014.30

DO - 10.1038/leu.2014.30

M3 - Article

VL - 28

SP - 1467

EP - 1471

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -